陈志敏, 何浩岚 . 艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022 , 21(04) : 425 -430 . DOI: 10.16150/j.1671-2870.2022.04.002
| [1] | DiSalvo AF, Fickling AM, Ajello L. Infection caused by penicillium marneffei: description of first natural infection in man[J]. Am J Clin Pathol, 1973, 60(2):259-263. |
| [2] | He L, Mei X, Lu S, et al. Talaromyces marneffei infection in non-HIV-infected patients in mainland China[J]. Mycoses, 2021, 64(10):1170-1176. |
| [3] | Li Y, Lin Z, Shi X, et al. Retrospective analysis of 15 cases of penicillium marneffei infection in HIV-positive and HIV-negative patients[J]. Microb Pathog, 2017, 105:321-325. |
| [4] | Lee PP, Lao-Araya M, Yang J, et al. Application of flow cytometry in the diagnostics pipeline of primary immunodeficiencies underlying disseminated talaromyces marneffei infection in HIV-negative children[J]. Front Immunol, 2019, 10:2189. |
| [5] | Ying RS, Le T, Cai WP, et al. Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017[J]. HIV Med, 2020, 21(11):729-738. |
| [6] | Qin Y, Huang X, Chen H, et al. Burden of talaromyces marneffei infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis[J]. BMC Infect Dis, 2020, 20(1):551. |
| [7] | Zheng J, Gui X, Cao Q, et al. A clinical study of acquired immunodeficiency syndrome associated penicil-lium marneffei infection from a non-endemic area in china[J]. PLoS One, 2015, 10(6):e0130376. |
| [8] | Li L, Chen K, Dhungana N, et al. Characterization of clinical isolates of Talaromyces marneffei and related species, California, USA[J]. Emerg Infect Dis, 2019, 25(9):1765-1768. |
| [9] | 黄丽芬, 唐小平, 蔡卫平, 等. 广东地区762例住院人类免疫缺陷病毒感染患者机会性感染分析[J]. 中华内科杂志, 2010, 49(8):653-656. |
| [9] | Huang LF, Tang XP, Cai WP, et al. An analysis of opportunistic infection in 762 inpatients with human immuno-deficiency virus infection in Guangdong areas[J]. Chin J Intern Med, 2010, 49(8):653-656. |
| [10] | Chariyalertsak S, Sirisanthana T, Saengwonloey O, et al. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994-1998: regional variation and temporal trends[J]. Clin Infect Dis, 2001, 32(6):955-962. |
| [11] | 陈志敏, 何浩岚, 刘波, 等. 2013—2018年广州市某医院HIV感染住院患者全因病死率及死亡原因分析[J]. 国际病毒学杂志, 2021, 28(6):453-458. |
| [11] | Chen ZM, He HL, Liu B, et al. Analysis on the all-cause mortality and causes of death among HIV-infected inpatients in a hosptial in Guangzhou, 2013-2018[J]. Intern J Virol, 2021, 28(6):453-458. |
| [12] | 何艳, 李凌华, 唐小平. 马尔尼菲青霉菌致病机制的研究进展[J]. 国际流行病学传染病学杂志, 2015, 42(4):256-259. |
| [12] | He Y, Li LH, Tang XP. Advances on the pathogenic mechanism of penicillium marneffei[J]. Intern J Epidemiol & Infect Dis, 2015, 42(4):256-259. |
| [13] | Shi M, Lin J, Wei W, et al. Machine learning-based in-hospital mortality prediction of HIV/AIDS patients with talaromyces marneffei infection in Guangxi, China[J]. PLoS Negl Trop Dis, 2022, 16(5):e0010388. |
| [14] | Narayanasamy S, Dat VQ, Thanh NT, et al. A global call for talaromycosis to be recognised as a neglected tropical disease[J]. Lancet Glob Health, 2021, 9(11):e1618-e1622. |
| [16] | Qiu Y, Zhang JQ, Pan ML, et al. Determinants of prognosis in talaromyces marneffei infections with respiratory system lesions[J]. Chin Med J (Engl), 2019, 132(16):1909-1918. |
| [15] | Andrianopoulos A. Control of morphogenesis in the human fungal pathogen penicillium marneffei[J]. Int J Med Microbiol, 2002, 292(5-6):331-347. |
| [17] | Hu Y, Zhang J, Li X, et al. Penicillium marneffei infection: an emerging disease in mainland China[J]. Mycopathologia, 2013, 175(1-2):57-67. |
| [18] | Le T, Wolbers M, Chi NH, et al. Epidemiology, seasona-lity, and predictors of outcome of AIDS-associated penicillium marneffei infection in Ho Chi Minh City, Viet Nam[J]. Clin Infect Dis, 2011, 52(7):945-952. |
| [19] | Le T, Huu Chi N, Kim Cuc NT, et al. AIDS-associated penicillium marneffei infection of the central nervous system[J]. Clin Infect Dis, 2010, 51(12):1458-1462. |
| [20] | 刘晋新, 唐小平, 江松峰, 等. 艾滋病合并马尔尼菲青霉菌感染的胸部影像学表现[J]. 中华放射学杂志, 2007, 41(3):239-242. |
| [20] | Liu JX, Tang XP, Jiang SF, et al. The chest image appearances of penicilliosis marneffei in patients with AIDS[J]. Chin J Radiol, 2007, 41(3):239-242. |
| [21] | 谢浩锋, 郑晓林, 黄翔, 等. 艾滋病合并马尔尼菲蓝状菌病的腹部CT及MRI征象分析[J]. 影像诊断与介入放射学, 2017, 26(4):282-286. |
| [21] | Xie HF, Zhen XL, Huang X, et al. Analysis of abdomen CT and MRI features in AIDS complicated by talaromycosis marneffei[J]. Diagn Imaging & Interv Radiol, 2017, 26(4):282-286. |
| [22] | 李凌华. 艾滋病合并马尔尼菲青霉菌病的临床及影响预后因素研究[D]. 广州: 中山大学, 2008. |
| [22] | Li LH. Clinical features and prognosis-related factors of Penicillious marneffei in AIDS patients[D]. Guangdong: SunYat-sen University, 2008. |
| [23] | Supparatpinyo K, Khamwan C, Baosoung V, et al. Disseminated penicillium marneffei infection in southeast Asia[J]. Lancet, 1994, 344(8915):110-113. |
| [24] | 何凯茵, 冯理智, 梁志伟, 等. 血清半乳甘露聚糖试验在诊断艾滋病合并马尔尼菲青霉菌病中的价值探讨[J]. 广州医科大学学报, 2016, 44(3):21-24. |
| [24] | He KY, Feng LZ, Liang ZW, et al. Value of serum galactomannan test in diagnosis of AIDS complicated with penicilliosis marneffei[J]. Acad J Guangzhou Med College, 2016, 44(3):21-24. |
| [25] | 李凌华, 肖赛银, 何艳, 等. 血清Mp1p抗原检测对艾滋病合并马尔尼菲蓝状菌病的诊断价值[J]. 中华传染病杂志, 2017, 35(3):157-160. |
| [25] | Li LH, Xiao SY, He Y, et al. Diagnostic value of serum Mp1p antigen detection for talaromyces marneffei infection in acquired immune deficiency syndrome patients[J]. Chin J Infect Dis, 2017, 35(3):157-160. |
| [26] | Thu N, Chan J, Hien H, et al. Clinical performance of the Mp1p immunoassay for rapid diagnosis of talaromyces marneffei infection[J]. 2017. |
| [27] | Wang YF, Xu HF, Han ZG, et al. Serological surveillance for penicillium marneffei infection in HIV-infected patients during 2004-2011 in Guangzhou, China[J]. Clin Microbiol Infect, 2015, 21(5):484-489. |
| [28] | Thu N, Dat V, Chan J, et al. Asymptomatic talaromyces marneffei infection is associated with HIV mortality[C]. Hong Kong, China: Asia Pacific AIDS and Co-infections Conference, 2018. |
| [29] | 《中华传染病杂志》编辑委员会. 中国宏基因组学第二代测序技术检测感染病原体的临床应用专家共识[J]. 中华传染病杂志, 2020, 38(11):681-689. |
| [29] | Editorial Board of Chinese Journal of Infectious Diseases. Clinical practice expert consensus for the application of metagenomic next generation sequencing[J]. Chin J Infect Dis, 2020, 38(11):681-689. |
| [30] | Hien HTA, Thanh TT, Thu NTM, et al. Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of talaromyces marneffei MP1 gene in human plasma[J]. Mycoses, 2016, 59(12):773-780. |
| [31] | 李仕雄, 许超宇, 吕日英, 等. 马尔尼菲蓝状菌病预后模型的构建[J]. 实用医学杂志, 2019, 35(16):2603-2606. |
| [31] | Li SX, Xu CY, Lü RY, et al. Prognostic risk factors and prognosis models of talaromyces marneffei patients[J]. J Pract Med, 2019, 35(16):2603-2606. |
| [32] | Supparatpinyo K, Nelson KE, Merz WG, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens[J]. Antimicrob Agents Chemother, 1993, 37(11):2407-2411. |
| [33] | 陈万山, 唐小平, 卢业成, 等. 五种抗真菌药物对马尔尼菲青霉菌的体外抗菌活性观察[J]. 中华传染病杂志, 2008, 26(3):143-145. |
| [33] | Chen WS, Tang XP, Lu YC, et al. In vitro susceptibilities of 5 antifungal agents against 52 strains of penicillium marneffei[J]. Chin J Infect Dis, 2008, 26(3):143-145. |
| [34] | Le T, Kinh NV, Cuc NTK, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis[J]. N Engl J Med, 2017, 376(24):2329-2340. |
| [35] | Lei HL, Li LH, Chen WS, et al. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of talaromyces marneffei isolated from HIV-infec-ted patients in Guangdong, China[J]. Eur J Clin Microbiol Infect Dis, 2018, 37(6):1099-1102. |
| [36] | 王星, 董明亮. 33例艾滋病伴播散性马尔尼菲青霉菌病患者的临床分析及其对抗真菌治疗的影响[J]. 抗感染药学, 2019, 16(01):72-75. |
| [36] | Wang X, Dong ML. Clinical analysis on 33 AIDS patients with disseminated penicilliosis marneffei disease and its influence on anti-fungal therapy[J]. Anti-Infect Pharm, 2019, 16(01):72-75. |
| [37] | 中国医药教育协会感染疾病专业委员会. 抗菌药物药代动力学/药效学理论临床应用专家共识[J]. 中华结核和呼吸杂志, 2018, 41(6):409-446. |
| [37] | Professional Committee of Infectious Diseases of China Medical Education Association. Expert consensus on the pharmacokinetic / pharmacodynamic theory and clinical application of antibacterial drugs[J]. Chin J Tuberc & Respir Dis, 2018, 41(6):409-446. |
| [38] | Chen K, Zhang X, Ke X, et al. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society[J]. Ther Drug Monit, 2018, 40(6):663-674. |
| [39] | 中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中华内科杂志, 2021, 60(12):1106-1128. |
| [39] | AIDS and Hepatitis C Group, Infectious Disease Branch, Chinese Medical Association, China Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition)[J]. Chin J Intern Med, 2021, 60(12):1106-1128. |
| [40] | Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV[R/OL]. http://aidsinfo.nih.gov. |
/
| 〈 |
|
〉 |
